A PEGylated dendritic nanoparticulate carrier of fluorouracil.
about
Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug deliveryNanoparticles: pharmacological and toxicological significanceCurrent understanding of interactions between nanoparticles and the immune systemDendrimer ProdrugsDendrimers as tunable vectors of drug delivery systems and biomedical and ocular applicationsRecent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and ImagingNanomedicine in Central Nervous System (CNS) Disorders: A Present and Future ProspectiveRecent advances in dendrimer-based nanovectors for tumor-targeted drug and gene deliveryControlled Drug Release from Pharmaceutical NanocarriersAdvances in PEGylation of important biotech molecules: delivery aspectsToxicological considerations when creating nanoparticle-based drugs and drug delivery systemsNanotoxicity: An Interplay of Oxidative Stress, Inflammation and Cell DeathCationic PAMAM dendrimers disrupt key platelet functions.Encapsulation of acetylshikonin by polyamidoamine dendrimers for preparing prominent nanoparticles.Cytotoxicity and biodistribution studies on PEGylated EDA and PEG cored PAMAM dendrimers.Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel.Synthesis and characterization of thermoresponsive polyamidoamine-polyethylene glycol-poly(D,L-lactide) core-shell nanoparticles.Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by FluorescenceDesign, synthesis, and biological evaluation of a robust, biodegradable dendrimer.Enabling individualized therapy through nanotechnologyThe polyamidoamine-mediated inhibition of bcl-2 by small hairpin RNA to induce apoptosis in human lens epithelial cells.Dendrimers in medical nanotechnologySelective cytotoxicity of PAMAM G5 core--PAMAM G2.5 shell tecto-dendrimers on melanoma cells.Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient.Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics.Polymeric-based particulate systems for delivery of therapeutic proteins.Nanofabrication of methylglyoxal with chitosan biopolymer: a potential tool for enhancement of its anticancer effectPolymeric conjugates for drug deliveryCoarse-grained model for PEGylated lipids: effect of PEGylation on the size and shape of self-assembled structuresChemotherapeutic evaluation of a synthetic tubulysin analogue-dendrimer conjugate in c26 tumor bearing miceDendrimer-Functionalized Laponite Nanodisks as a Platform for Anticancer Drug Delivery.The transferrin receptor and the targeted delivery of therapeutic agents against cancer.Nanotechnology-based drug delivery systemsNanostructured materials for applications in drug delivery and tissue engineering.Design Strategies for Fluorescent Biodegradable Polymeric Biomaterials.Targeted pharmaceutical nanocarriers for cancer therapy and imagingDendritic systems in drug delivery applications.Nucleoside analogue delivery systems in cancer therapy.Nanovehicular intracellular delivery systems.Tumour and dendrimers: a review on drug delivery aspects.
P2860
Q24616011-8D83A3E4-F814-41CA-8172-BC44C42509E0Q24681563-A8617CCC-BAC3-4F5A-A603-F998014C8350Q26345204-928C04A9-CCE2-4D6E-AC64-8D14CF51E8FCQ26743392-B2F26A96-FD76-4F66-A794-7C3659D4E592Q26771189-5CB81632-4E76-4462-A45F-9CFBA379E919Q26778234-2C2C5EA5-1257-4E68-8936-47AE9449BAB4Q28075999-9F586922-A9C7-4754-A3F9-5FA2300EEDE3Q28085438-580F1C11-44D6-4692-BDCE-B35B9BD93F17Q28257050-12D38402-6290-4817-AE6D-73B4665D3177Q28277255-98AEE59D-A81F-413C-B28C-B335476FBFE8Q28395046-CA6E39BA-BC19-4D5E-9F82-273DAE6731F4Q29248384-3E0E8F36-6D64-4298-9192-6AE4BBE69431Q30514562-AF9B2A1F-9C0E-4B65-BBDD-35689B356340Q30739130-914D49F0-4765-4EE4-B39A-5CF5044174ACQ31122095-CD8B4400-9DFB-4F81-A7A3-1DA9AACD1CF0Q31151834-267648C6-D9D2-4948-8A54-80A7C7983085Q33498227-EABAFEF7-7147-403E-A813-5543D154F54AQ33759991-C3E69B78-45B5-4F01-A6B9-C7CD2BFB6A75Q33910306-2B0A3DCF-DF83-4DE6-97BD-020F5BB07E42Q33917755-84FD3735-1B08-4A5C-893F-60D2F544CAD6Q34134038-B38CEF95-C1FA-444A-8C94-3DA0770F3302Q34369684-4CDCDD80-8380-4663-8226-B4BCC7BCFAE7Q34384077-EA7A87B6-57CC-48C1-A00F-AC0EF39F44B4Q34476287-60694CB1-8AEC-463B-B0A3-5DB8E4C0D6B1Q34827321-227B9D5B-F319-47EF-ABC7-7E7959AD3A11Q35539532-906ECD32-E7EB-4467-99E8-800796CBA16FQ35618088-04C81BDF-1F2A-412F-99DB-DB2DF56C460DQ36029175-88075BFA-FE32-41ED-951D-3B8908EC6894Q36290628-6DD8D54C-B063-4173-9D40-A1A4665C854AQ36315671-229EBBAD-76F7-4B9C-B2C1-E6C3F1DD8FEFQ36324230-007F1B27-E813-4F01-9D87-6DC619785D53Q36406637-45F5D92B-78A4-469E-A26B-82BB144DD9D2Q36419770-2746D2C3-6F47-4EC0-9A81-834700F83FCEQ36807625-E0210AF9-5C7D-4B9D-B97C-73BB1933AAB9Q36864841-89C77F3A-CDCE-452F-85F0-2AAC2B7B404CQ36871933-6D1EB606-BD3B-4C9F-9AAE-EE2979FDF4A6Q36945843-6CA20332-35A2-4250-82B2-7891032F6761Q36945847-C18E1321-D17D-4AE8-9D88-303376E14CE0Q37058812-60241340-B9CA-4186-AE97-BC8047F77382Q37171165-4319B2A8-33B6-422A-AC7E-A633493A2D91
P2860
A PEGylated dendritic nanoparticulate carrier of fluorouracil.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
A PEGylated dendritic nanoparticulate carrier of fluorouracil.
@en
A PEGylated dendritic nanoparticulate carrier of fluorouracil.
@nl
type
label
A PEGylated dendritic nanoparticulate carrier of fluorouracil.
@en
A PEGylated dendritic nanoparticulate carrier of fluorouracil.
@nl
prefLabel
A PEGylated dendritic nanoparticulate carrier of fluorouracil.
@en
A PEGylated dendritic nanoparticulate carrier of fluorouracil.
@nl
P2093
P1476
A PEGylated dendritic nanoparticulate carrier of fluorouracil.
@en
P2093
P304
P356
10.1016/S0378-5173(03)00132-7
P407
P577
2003-05-01T00:00:00Z